{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:25:12Z","timestamp":1782908712056,"version":"3.54.5"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,9,20]],"date-time":"2014-09-20T00:00:00Z","timestamp":1411171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2014,9,20]],"date-time":"2014-09-20T00:00:00Z","timestamp":1411171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Med. Toxicol."],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s13181-014-0430-3","type":"journal-article","created":{"date-parts":[[2014,9,19]],"date-time":"2014-09-19T19:10:00Z","timestamp":1411153800000},"page":"369-381","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Is It Prime Time for Alpha2-Adrenocepter Agonists in the Treatment of Withdrawal Syndromes?"],"prefix":"10.1007","volume":"10","author":[{"given":"Timothy E.","family":"Albertson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Chenoweth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Sutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,20]]},"reference":[{"issue":"1","key":"430_CR1","first-page":"13","volume":"14","author":"R Gertler","year":"2001","unstructured":"Gertler R et al (2001) Dexmedetomidine: a novel sedative-analgesic agent. Proc (Bayl Univ Med Cent) 14(1):13\u201321","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"430_CR2","unstructured":"Fodd and Drug Administration. 2014. [cited June 2014]; Available from: http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm."},{"issue":"4","key":"430_CR3","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1124\/mol.113.090118","volume":"85","author":"KT Schmidt","year":"2014","unstructured":"Schmidt KT, Weinshenker D (2014) Adrenaline rush: the role of adrenergic receptors in stimulant-induced behaviors. Mol Pharmacol 85(4):640\u201350","journal-title":"Mol Pharmacol"},{"issue":"4","key":"430_CR4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1755-5922.2011.00269.x","volume":"30","author":"K Nikolic","year":"2012","unstructured":"Nikolic K, Agbaba D (2012) Imidazoline antihypertensive drugs: selective i (1)-imidazoline receptors activation. Cardiovasc Ther 30(4):209\u201316","journal-title":"Cardiovasc Ther"},{"issue":"4","key":"430_CR5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1755-5922.2011.00268.x","volume":"30","author":"LP Edwards","year":"2012","unstructured":"Edwards LP et al (2012) Pharmacological properties of the central antihypertensive agent, moxonidine. Cardiovasc Ther 30(4):199\u2013208","journal-title":"Cardiovasc Ther"},{"issue":"2","key":"430_CR6","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S0022-3565(25)10205-X","volume":"264","author":"ER Butelman","year":"1993","unstructured":"Butelman ER, Woods JH (1993) Effects of clonidine, dexmedetomidine and xylazine on thermal antinociception in rhesus monkeys. J Pharmacol Exp Ther 264(2):762\u20139","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"430_CR7","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/S0002-9343(03)00165-7","volume":"114","author":"DN Wijeysundera","year":"2003","unstructured":"Wijeysundera DN, Naik JS, Beattie WS (2003) Alpha-2 adrenergic agonists to prevent perioperative cardiovascular complications: a meta-analysis. Am J Med 114(9):742\u201352","journal-title":"Am J Med"},{"issue":"2","key":"430_CR8","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00003495-200059020-00012","volume":"59","author":"N Bhana","year":"2000","unstructured":"Bhana N, Goa KL, McClellan KJ (2000) Dexmedetomidine. Drugs 59(2):263\u20138, discussion 269\u201370","journal-title":"Drugs"},{"key":"430_CR9","unstructured":"Chabot-Dore AJ, et al. Analgesic synergy between opioid and alpha-2 adrenergic receptors. Br J Pharmacol, 2014."},{"issue":"12","key":"430_CR10","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1345\/aph.1M310","volume":"43","author":"AT Gerlach","year":"2009","unstructured":"Gerlach AT, Murphy CV, Dasta JF (2009) An updated focused review of dexmedetomidine in adults. Ann Pharmacother 43(12):2064\u201374","journal-title":"Ann Pharmacother"},{"issue":"1","key":"430_CR11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/PCC.0b013e3181b062d7","volume":"11","author":"K Hosokawa","year":"2010","unstructured":"Hosokawa K et al (2010) Dexmedetomidine sedation in children after cardiac surgery. Pediatr Crit Care Med 11(1):39\u201343","journal-title":"Pediatr Crit Care Med"},{"issue":"1","key":"430_CR12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1017\/S0265021507001317","volume":"25","author":"S Goksu","year":"2008","unstructured":"Goksu S et al (2008) Effects of dexmedetomidine infusion in patients undergoing functional endoscopic sinus surgery under local anaesthesia. Eur J Anaesthesiol 25(1):22\u20138","journal-title":"Eur J Anaesthesiol"},{"key":"430_CR13","doi-asserted-by":"crossref","unstructured":"Wijeysundera DN, Bender JS, Beattie WS. Alpha-2 adrenergic agonists for the prevention of cardiac complications among patients undergoing surgery. Cochrane Database Syst Rev, 2009 (4): p. Cd004126.","DOI":"10.1002\/14651858.CD004126.pub2"},{"issue":"11","key":"430_CR14","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2165\/11207190-000000000-00000","volume":"71","author":"SM Hoy","year":"2011","unstructured":"Hoy SM, Keating GM (2011) Dexmedetomidine: a review of its use for sedation in mechanically ventilated patients in an intensive care setting and for procedural sedation. Drugs 71(11):1481\u2013501","journal-title":"Drugs"},{"issue":"1","key":"430_CR15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s00540-013-1678-5","volume":"28","author":"M Ozaki","year":"2014","unstructured":"Ozaki M et al (2014) Safety and efficacy of dexmedetomidine for long-term sedation in critically ill patients. J Anesth 28(1):38\u201350","journal-title":"J Anesth"},{"issue":"6","key":"430_CR16","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/PCC.0b013e318253c7f1","volume":"13","author":"P Gupta","year":"2012","unstructured":"Gupta P et al (2012) Safety and efficacy of prolonged dexmedetomidine use in critically ill children with heart disease*. Pediatr Crit Care Med 13(6):660\u20136","journal-title":"Pediatr Crit Care Med"},{"issue":"12","key":"430_CR17","doi-asserted-by":"crossref","first-page":"e82913","DOI":"10.1371\/journal.pone.0082913","volume":"8","author":"L Pasin","year":"2013","unstructured":"Pasin L et al (2013) Dexmedetomidine as a sedative agent in critically ill patients: a meta-analysis of randomized controlled trials. PLoS One 8(12):e82913","journal-title":"PLoS One"},{"issue":"6","key":"430_CR18","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1007\/s00134-010-1877-6","volume":"36","author":"JA Tan","year":"2010","unstructured":"Tan JA, Ho KM (2010) Use of dexmedetomidine as a sedative and analgesic agent in critically ill adult patients: a meta-analysis. Intensive Care Med 36(6):926\u201339","journal-title":"Intensive Care Med"},{"issue":"6","key":"430_CR19","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1345\/aph.1AR708","volume":"47","author":"Y Mo","year":"2013","unstructured":"Mo Y, Zimmermann AE (2013) Role of dexmedetomidine for the prevention and treatment of delirium in intensive care unit patients. Ann Pharmacother 47(6):869\u201376","journal-title":"Ann Pharmacother"},{"issue":"10","key":"430_CR20","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/j.1399-6576.2004.00525.x","volume":"48","author":"HT Bergendahl","year":"2004","unstructured":"Bergendahl HT et al (2004) Clonidine vs. midazolam as premedication in children undergoing adeno-tonsillectomy: a prospective, randomized, controlled clinical trial. Acta Anaesthesiol Scand 48(10):1292\u2013300","journal-title":"Acta Anaesthesiol Scand"},{"key":"430_CR21","doi-asserted-by":"crossref","unstructured":"Hunseler C, et al. Continuous infusion of clonidine in ventilated newborns and infants: a randomized controlled trial. Pediatr Crit Care Med. 2014.","DOI":"10.1097\/PCC.0000000000000151"},{"issue":"4","key":"430_CR22","doi-asserted-by":"crossref","first-page":"439","DOI":"10.4103\/0970-9185.74581","volume":"26","author":"S Jamadarkhana","year":"2010","unstructured":"Jamadarkhana S, Gopal S (2010) Clonidine in adults as a sedative agent in the intensive care unit. J Anaesthesiol Clin Pharmacol 26(4):439\u201345","journal-title":"J Anaesthesiol Clin Pharmacol"},{"issue":"4","key":"430_CR23","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/0885066610396815","volume":"27","author":"C Pichot","year":"2012","unstructured":"Pichot C, Ghignone M, Quintin L (2012) Dexmedetomidine and clonidine: from second- to first-line sedative agents in the critical care setting? J Intensive Care Med 27(4):219\u201337","journal-title":"J Intensive Care Med"},{"issue":"3","key":"430_CR24","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11524-011-9662-6","volume":"89","author":"JC Reyes","year":"2012","unstructured":"Reyes JC et al (2012) The emerging of xylazine as a new drug of abuse and its health consequences among drug users in Puerto Rico. J Urban Health 89(3):519\u201326","journal-title":"J Urban Health"},{"key":"430_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.forsciint.2014.03.015","volume":"240","author":"K Ruiz-Colon","year":"2014","unstructured":"Ruiz-Colon K et al (2014) Xylazine intoxication in humans and its importance as an emerging adulterant in abused drugs: a comprehensive review of the literature. Forensic Sci Int 240:1\u20138","journal-title":"Forensic Sci Int"},{"issue":"5","key":"430_CR26","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s40263-014-0163-5","volume":"28","author":"EC Perry","year":"2014","unstructured":"Perry EC (2014) Inpatient management of acute alcohol withdrawal syndrome. CNS Drugs 28(5):401\u201310","journal-title":"CNS Drugs"},{"issue":"4","key":"430_CR27","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/acer.12002","volume":"37","author":"LA Ungur","year":"2013","unstructured":"Ungur LA et al (2013) Prevention and therapy of alcohol withdrawal on intensive care units: systematic review of controlled trials. Alcohol Clin Exp Res 37(4):675\u201386","journal-title":"Alcohol Clin Exp Res"},{"issue":"9","key":"430_CR28","first-page":"589","volume":"88","author":"HL Muncie Jr","year":"2013","unstructured":"Muncie HL Jr, Yasinian Y, Oge L (2013) Outpatient management of alcohol withdrawal syndrome. Am Fam Physician 88(9):589\u201395","journal-title":"Am Fam Physician"},{"issue":"15","key":"430_CR29","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/archinte.159.15.1681","volume":"159","author":"MC Reid","year":"1999","unstructured":"Reid MC, Fiellin DA, O'Connor PG (1999) Hazardous and harmful alcohol consumption in primary care. Arch Intern Med 159(15):1681\u20139","journal-title":"Arch Intern Med"},{"issue":"4","key":"430_CR30","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1213\/00000539-199904000-00050","volume":"88","author":"CD Spies","year":"1999","unstructured":"Spies CD, Rommelspacher H (1999) Alcohol withdrawal in the surgical patient: prevention and treatment. Anesth Analg 88(4):946\u201354","journal-title":"Anesth Analg"},{"issue":"18","key":"430_CR31","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMra020617","volume":"348","author":"TR Kosten","year":"2003","unstructured":"Kosten TR, O'Connor PG (2003) Management of drug and alcohol withdrawal. N Engl J Med 348(18):1786\u201395","journal-title":"N Engl J Med"},{"key":"430_CR32","first-page":"171","volume":"7","author":"PJ Fitzgerald","year":"2013","unstructured":"Fitzgerald PJ (2013) Elevated norepinephrine may be a unifying etiological factor in the abuse of a broad range of substances: alcohol, nicotine, marijuana, heroin, cocaine, and caffeine. Subst Abuse 7:171\u201383","journal-title":"Subst Abuse"},{"issue":"1","key":"430_CR33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s00134-012-2758-y","volume":"39","author":"DK Awissi","year":"2013","unstructured":"Awissi DK et al (2013) Alcohol withdrawal and delirium tremens in the critically ill: a systematic review and commentary. Intensive Care Med 39(1):16\u201330","journal-title":"Intensive Care Med"},{"issue":"9","key":"430_CR34","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1097\/CCM.0b013e3182a16919","volume":"41","author":"DK Awissi","year":"2013","unstructured":"Awissi DK et al (2013) Alcohol, nicotine, and iatrogenic withdrawals in the ICU. Crit Care Med 41(9):S57\u201368","journal-title":"Crit Care Med"},{"issue":"11","key":"430_CR35","first-page":"1233","volume":"80","author":"M Mondavio","year":"1989","unstructured":"Mondavio M, Ghiazza GF (1989) [Use of clonidine in the prevention of alcohol withdrawal syndrome]. Minerva Med 80(11):1233\u20135","journal-title":"Minerva Med"},{"issue":"2","key":"430_CR36","first-page":"258","volume":"82","author":"N Mertes","year":"1996","unstructured":"Mertes N et al (1996) Postoperative alpha 2-adrenergic stimulation attenuates protein catabolism. Anesth Analg 82(2):258\u201363","journal-title":"Anesth Analg"},{"issue":"6","key":"430_CR37","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1093\/bja\/75.6.734","volume":"75","author":"CD Spies","year":"1995","unstructured":"Spies CD et al (1995) Prophylaxis of alcohol withdrawal syndrome in alcohol-dependent patients admitted to the intensive care unit after tumour resection. Br J Anaesth 75(6):734\u20139","journal-title":"Br J Anaesth"},{"issue":"1","key":"430_CR38","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/bja\/68.1.106","volume":"68","author":"PC Ip Yam","year":"1992","unstructured":"Ip Yam PC, Forbes A, Kox WJ (1992) Clonidine in the treatment of alcohol withdrawal in the intensive care unit. Br J Anaesth 68(1):106\u20138","journal-title":"Br J Anaesth"},{"issue":"1","key":"430_CR39","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/BF00439278","volume":"81","author":"AJ Wilkins","year":"1983","unstructured":"Wilkins AJ, Jenkins WJ, Steiner JA (1983) Efficacy of clonidine in treatment of alcohol withdrawal state. Psychopharmacology (Berl) 81(1):78\u201380","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"430_CR40","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/j.1530-0277.1994.tb00053.x","volume":"18","author":"B Adinoff","year":"1994","unstructured":"Adinoff B (1994) Double-blind study of alprazolam, diazepam, clonidine, and placebo in the alcohol withdrawal syndrome: preliminary findings. Alcohol Clin Exp Res 18(4):873\u20138","journal-title":"Alcohol Clin Exp Res"},{"issue":"7","key":"430_CR41","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/archinte.1987.00370070037005","volume":"147","author":"GR Baumgartner","year":"1987","unstructured":"Baumgartner GR, Rowen RC (1987) Clonidine vs chlordiazepoxide in the management of acute alcohol withdrawal syndrome. Arch Intern Med 147(7):1223\u20136","journal-title":"Arch Intern Med"},{"issue":"3","key":"430_CR42","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/00007611-199103000-00006","volume":"84","author":"GR Baumgartner","year":"1991","unstructured":"Baumgartner GR, Rowen RC (1991) Transdermal clonidine versus chlordiazepoxide in alcohol withdrawal: a randomized, controlled clinical trial. South Med J 84(3):312\u201321","journal-title":"South Med J"},{"issue":"3","key":"430_CR43","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1530-0277.1985.tb05743.x","volume":"9","author":"P Manhem","year":"1985","unstructured":"Manhem P et al (1985) Alcohol withdrawal: effects of clonidine treatment on sympathetic activity, the renin-aldosterone system, and clinical symptoms. Alcohol Clin Exp Res 9(3):238\u201343","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"430_CR44","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/00007611-198801000-00012","volume":"81","author":"GR Baumgartner","year":"1988","unstructured":"Baumgartner GR (1988) Clonidine versus chlordiazepoxide in acute alcohol withdrawal: a preliminary report. South Med J 81(1):56\u201360","journal-title":"South Med J"},{"issue":"4","key":"430_CR45","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1600-0447.1975.tb00041.x","volume":"52","author":"SE Bjorkqvist","year":"1975","unstructured":"Bjorkqvist SE (1975) Clonidine in alcohol withdrawal. Acta Psychiatr Scand 52(4):256\u201363","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"430_CR46","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/00003246-199603000-00009","volume":"24","author":"CD Spies","year":"1996","unstructured":"Spies CD et al (1996) Therapy of alcohol withdrawal syndrome in intensive care unit patients following trauma: results of a prospective, randomized trial. Crit Care Med 24(3):414\u201322","journal-title":"Crit Care Med"},{"issue":"8","key":"430_CR47","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/archotol.134.8.865","volume":"134","author":"CD Lansford","year":"2008","unstructured":"Lansford CD et al (2008) Improved outcomes in patients with head and neck cancer using a standardized care protocol for postoperative alcohol withdrawal. Arch Otolaryngol Head Neck Surg 134(8):865\u201372","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"2","key":"430_CR48","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s001010050672","volume":"48","author":"E Lenzenhuber","year":"1999","unstructured":"Lenzenhuber E et al (1999) Gamma-hydroxybutyrate for treatment of alcohol withdrawal syndrome in intensive care patients. A comparison between with two symptom-oriented therapeutic concepts. Anaesthesist 48(2):89\u201396","journal-title":"Anaesthesist"},{"issue":"12","key":"430_CR49","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1007\/s00134-003-2033-3","volume":"29","author":"CD Spies","year":"2003","unstructured":"Spies CD et al (2003) Alcohol withdrawal severity is decreased by symptom-orientated adjusted bolus therapy in the ICU. Intensive Care Med 29(12):2230\u20138","journal-title":"Intensive Care Med"},{"issue":"6","key":"430_CR50","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0741-8329(97)00044-X","volume":"14","author":"P Riihioja","year":"1997","unstructured":"Riihioja P et al (1997) Dexmedetomidine alleviates ethanol withdrawal symptoms in the rat. Alcohol 14(6):537\u201344","journal-title":"Alcohol"},{"issue":"11","key":"430_CR51","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s40263-013-0106-6","volume":"27","author":"AJ Muzyk","year":"2013","unstructured":"Muzyk AJ et al (2013) Dexmedetomidine for the treatment of alcohol withdrawal syndrome: rationale and current status of research. CNS Drugs 27(11):913\u201320","journal-title":"CNS Drugs"},{"issue":"4","key":"430_CR52","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00540-012-1381-y","volume":"26","author":"JP DeMuro","year":"2012","unstructured":"DeMuro JP et al (2012) Use of dexmedetomidine for the treatment of alcohol withdrawal syndrome in critically ill patients: a retrospective case series. J Anesth 26(4):601\u20135","journal-title":"J Anesth"},{"issue":"2","key":"430_CR53","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jcrc.2013.11.016","volume":"29","author":"EN Frazee","year":"2014","unstructured":"Frazee EN et al (2014) Influence of dexmedetomidine therapy on the management of severe alcohol withdrawal syndrome in critically ill patients. J Crit Care 29(2):298\u2013302","journal-title":"J Crit Care"},{"issue":"6","key":"430_CR54","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/MEJ.0b013e32835c53b3","volume":"20","author":"J Tolonen","year":"2013","unstructured":"Tolonen J et al (2013) Dexmedetomidine in addition to benzodiazepine-based sedation in patients with alcohol withdrawal delirium. Eur J Emerg Med 20(6):425\u20137","journal-title":"Eur J Emerg Med"},{"issue":"1","key":"430_CR55","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/2110-5820-2-12","volume":"2","author":"SG Rayner","year":"2012","unstructured":"Rayner SG et al (2012) Dexmedetomidine as adjunct treatment for severe alcohol withdrawal in the ICU. Ann Intensive Care 2(1):12","journal-title":"Ann Intensive Care"},{"issue":"6","key":"430_CR56","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1007\/s00464-012-2734-1","volume":"27","author":"M Mazanikov","year":"2013","unstructured":"Mazanikov M et al (2013) Dexmedetomidine impairs success of patient-controlled sedation in alcoholics during ERCP: a randomized, double-blind, placebo-controlled study. Surg Endosc 27(6):2163\u20138","journal-title":"Surg Endosc"},{"issue":"5","key":"430_CR57","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1097\/CCM.0000000000000141","volume":"42","author":"SW Mueller","year":"2014","unstructured":"Mueller SW et al (2014) A randomized, double-blind, placebo-controlled dose range study of dexmedetomidine as adjunctive therapy for alcohol withdrawal. Crit Care Med 42(5):1131\u20139","journal-title":"Crit Care Med"},{"issue":"5","key":"430_CR58","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1097\/CCM.0000000000000173","volume":"42","author":"RH Savel","year":"2014","unstructured":"Savel RH, Kupfer Y (2014) Using dexmedetomidine as adjunctive therapy for patients with severe alcohol withdrawal syndrome: another piece of the puzzle. Crit Care Med 42(5):1298\u20139","journal-title":"Crit Care Med"},{"issue":"4","key":"430_CR59","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.mehy.2011.06.028","volume":"77","author":"R Bou Khalil","year":"2011","unstructured":"Bou Khalil R (2011) Tizanidine for alcohol withdrawal treatment. Med Hypotheses 77(4):548\u20139","journal-title":"Med Hypotheses"},{"issue":"2","key":"430_CR60","first-page":"167","volume":"21","author":"J Brunning","year":"1986","unstructured":"Brunning J, Mumford JP, Keaney FP (1986) Lofexidine in alcohol withdrawal states. Alcohol Alcohol 21(2):167\u201370","journal-title":"Alcohol Alcohol"},{"issue":"2","key":"430_CR61","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1530-0277.1985.tb05527.x","volume":"9","author":"P Cushman Jr","year":"1985","unstructured":"Cushman P Jr et al (1985) Alcohol withdrawal syndromes: clinical management with lofexidine. Alcohol Clin Exp Res 9(2):103\u20138","journal-title":"Alcohol Clin Exp Res"},{"issue":"5","key":"430_CR62","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/alcalc\/36.5.426","volume":"36","author":"F Keaney","year":"2001","unstructured":"Keaney F et al (2001) A double-blind randomized placebo-controlled trial of lofexidine in alcohol withdrawal: lofexidine is not a useful adjunct to chlordiazepoxide. Alcohol Alcohol 36(5):426\u201330","journal-title":"Alcohol Alcohol"},{"issue":"5","key":"430_CR63","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1345\/aph.1P575","volume":"45","author":"AJ Muzyk","year":"2011","unstructured":"Muzyk AJ et al (2011) Role of alpha2-agonists in the treatment of acute alcohol withdrawal. Ann Pharmacother 45(5):649\u201357","journal-title":"Ann Pharmacother"},{"issue":"1","key":"430_CR64","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2174\/1871527311312010017","volume":"12","author":"AK Rehni","year":"2013","unstructured":"Rehni AK, Jaggi AS, Singh N (2013) Opioid withdrawal syndrome: emerging concepts and novel therapeutic targets. CNS Neurol Disord Drug Targets 12(1):112\u201325","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"3","key":"430_CR65","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/archinte.164.3.277","volume":"164","author":"MJ Krantz","year":"2004","unstructured":"Krantz MJ, Mehler PS (2004) Treating opioid dependence. Growing implications for primary care. Arch Intern Med 164(3):277\u201388","journal-title":"Arch Intern Med"},{"issue":"8090","key":"430_CR66","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0140-6736(78)92823-4","volume":"2","author":"MS Gold","year":"1978","unstructured":"Gold MS, Redmond DE Jr, Kleber HD (1978) Clonidine blocks acute opiate-withdrawal symptoms. Lancet 2(8090):599\u2013602","journal-title":"Lancet"},{"issue":"3","key":"430_CR67","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3109\/00952990.2011.644003","volume":"38","author":"P Mannelli","year":"2012","unstructured":"Mannelli P et al (2012) The combination very low-dose naltrexone-clonidine in the management of opioid withdrawal. Am J Drug Alcohol Abuse 38(3):200\u20135","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"5","key":"430_CR68","doi-asserted-by":"crossref","first-page":"292","DOI":"10.5055\/jom.2012.0129","volume":"8","author":"MC Monterubbianesi","year":"2012","unstructured":"Monterubbianesi MC et al (2012) High opioid dosage rapid detoxification of cancer patient in palliative care with the Raffaeli model. J Opioid Manag 8(5):292\u20138","journal-title":"J Opioid Manag"},{"issue":"7\u20138","key":"430_CR69","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1345\/aph.1M758","volume":"44","author":"K O'Mara","year":"2010","unstructured":"O'Mara K, Gal P, Davanzo C (2010) Treatment of neonatal withdrawal with clonidine after long-term, high-dose maternal use of tramadol. Ann Pharmacother 44(7\u20138):1342\u20134","journal-title":"Ann Pharmacother"},{"issue":"11","key":"430_CR70","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1001\/archotol.1996.01890230080015","volume":"122","author":"ES Deutsch","year":"1996","unstructured":"Deutsch ES, Nadkarni VM (1996) Clonidine prophylaxis for narcotic and sedative withdrawal syndrome following laryngotracheal reconstruction. Arch Otolaryngol Head Neck Surg 122(11):1234\u20138","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"3","key":"430_CR71","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000259168","volume":"3","author":"A Malhotra","year":"1997","unstructured":"Malhotra A et al (1997) Clonidine versus withdrawal using an opioid in in-patient opioid detoxification. Eur Addict Res 3(3):146\u2013149","journal-title":"Eur Addict Res"},{"issue":"3\u20134","key":"430_CR72","first-page":"79","volume":"4","author":"H Ziaaddini","year":"2012","unstructured":"Ziaaddini H, Nasirian M, Nakhaee N (2012) Comparison of the efficacy of buprenorphine and clonidine in detoxification of opioid-dependents. Addict Health 4(3\u20134):79\u201386","journal-title":"Addict Health"},{"issue":"5","key":"430_CR73","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1176\/ajp.148.5.627","volume":"148","author":"F Hartmann","year":"1991","unstructured":"Hartmann F et al (1991) Comparison of acetorphan with clonidine for opiate withdrawal symptoms. Am J Psychiatry 148(5):627\u20139","journal-title":"Am J Psychiatry"},{"issue":"5","key":"430_CR74","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1365-2710.2000.00295.x","volume":"25","author":"S Akhondzadeh","year":"2000","unstructured":"Akhondzadeh S et al (2000) Double-blind randomized controlled trial of baclofen vs. clonidine in the treatment of opiates withdrawal. J Clin Pharm Ther 25(5):347\u201353","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"430_CR75","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0376-8716(88)90078-6","volume":"21","author":"M Gossop","year":"1988","unstructured":"Gossop M (1988) Clonidine and the treatment of the opiate withdrawal syndrome. Drug Alcohol Depend 21(3):253\u20139","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"430_CR76","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/105504999305749","volume":"8","author":"J Strang","year":"1999","unstructured":"Strang J, Bearn J, Gossop M (1999) Lofexidine for opiate detoxification: review of recent randomised and open controlled trials. Am J Addict 8(4):337\u201348","journal-title":"Am J Addict"},{"issue":"2","key":"430_CR77","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1345\/aph.1M347","volume":"44","author":"EC Gish","year":"2010","unstructured":"Gish EC et al (2010) Lofexidine, an {alpha}2-receptor agonist for opioid detoxification. Ann Pharmacother 44(2):343\u201351","journal-title":"Ann Pharmacother"},{"issue":"9","key":"430_CR78","first-page":"335","volume":"44","author":"AM Washton","year":"1983","unstructured":"Washton AM, Resnick RB, Geyer G (1983) Opiate withdrawal using lofexidine, a clonidine analogue with fewer side effects. J Clin Psychiatry 44(9):335\u20137","journal-title":"J Clin Psychiatry"},{"issue":"1\u20132","key":"430_CR79","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.drugalcdep.2008.04.002","volume":"97","author":"E Yu","year":"2008","unstructured":"Yu E et al (2008) A phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal. Drug Alcohol Depend 97(1\u20132):158\u201368","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"430_CR80","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.drugalcdep.2006.09.020","volume":"88","author":"J McCambridge","year":"2007","unstructured":"McCambridge J et al (2007) In-patient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, lofexidine + placebo, and methadone. Drug Alcohol Depend 88(1):91\u20135","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"430_CR81","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0376-8716(02)00024-8","volume":"67","author":"C Howells","year":"2002","unstructured":"Howells C et al (2002) Prison based detoxification for opioid dependence: a randomised double blind controlled trial of lofexidine and methadone. Drug Alcohol Depend 67(2):169\u201376","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"430_CR82","first-page":"205","volume":"3","author":"F Doosti","year":"2013","unstructured":"Doosti F et al (2013) Traditional Chinese and Indian medicine in the treatment of opioid-dependence: a review. Avicenna J Phytomed 3(3):205\u201315","journal-title":"Avicenna J Phytomed"},{"issue":"1","key":"430_CR83","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10571-008-9290-1","volume":"29","author":"TT Liu","year":"2009","unstructured":"Liu TT et al (2009) A meta-analysis of Chinese herbal medicine in treatment of managed withdrawal from heroin. Cell Mol Neurobiol 29(1):17\u201325","journal-title":"Cell Mol Neurobiol"},{"issue":"6","key":"430_CR84","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1080\/00952990802491563","volume":"34","author":"J Shi","year":"2008","unstructured":"Shi J et al (2008) A comparative clinical study of the effects of the traditional Chinese medicine Jinniu capsules and lofexidine on acute heroin withdrawal symptoms. Am J Drug Alcohol Abuse 34(6):792\u2013800","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"2","key":"430_CR85","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0376-8716(97)00116-6","volume":"48","author":"SK Lin","year":"1997","unstructured":"Lin SK et al (1997) Double-blind randomised controlled trial of lofexidine versus clonidine in the treatment of heroin withdrawal. Drug Alcohol Depend 48(2):127\u201333","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"430_CR86","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0376-8716(98)00040-4","volume":"50","author":"T Carnwath","year":"1998","unstructured":"Carnwath T, Hardman J (1998) Randomised double-blind comparison of lofexidine and clonidine in the out-patient treatment of opiate withdrawal. Drug Alcohol Depend 50(3):251\u20134","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"430_CR87","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1360-0443.2003.00372.x","volume":"98","author":"SL Walsh","year":"2003","unstructured":"Walsh SL, Strain EC, Bigelow GE (2003) Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans. Addiction 98(4):427\u201339","journal-title":"Addiction"},{"issue":"1","key":"430_CR88","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1360-0443.1990.tb00634.x","volume":"85","author":"L San","year":"1990","unstructured":"San L et al (1990) Efficacy of clonidine, guanfacine and methadone in the rapid detoxification of heroin addicts: a controlled clinical trial. Br J Addict 85(1):141\u20137","journal-title":"Br J Addict"},{"issue":"5","key":"430_CR89","first-page":"169","volume":"94","author":"R Muga","year":"1990","unstructured":"Muga R et al (1990) Comparative effectiveness of alpha-2 adrenergic agonists (clonidine-guanfacine) in the hospital detoxification of opiate addicts. Med Clin (Barc) 94(5):169\u201372","journal-title":"Med Clin (Barc)"},{"issue":"1","key":"430_CR90","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0376-8716(98)00010-6","volume":"50","author":"A Pinelli","year":"1998","unstructured":"Pinelli A, Trivulzio S, Spezia R (1998) Effects of tizanidine administration on precipitated opioid withdrawal signs in rats. Drug Alcohol Depend 50(1):81\u20138","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"430_CR91","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/0091-3057(92)90016-9","volume":"42","author":"H Koyuncuoglu","year":"1992","unstructured":"Koyuncuoglu H et al (1992) Effects of tizanidine on morphine physical dependence: attenuation and intensification. Pharmacol Biochem Behav 42(4):693\u20138","journal-title":"Pharmacol Biochem Behav"},{"issue":"15","key":"430_CR92","first-page":"783","volume":"141","author":"I Sos","year":"2000","unstructured":"Sos I et al (2000) [Tizanidine in the treatment of acute withdrawal symptoms in heroin dependent patients]. Orv Hetil 141(15):783\u20136","journal-title":"Orv Hetil"},{"issue":"1","key":"430_CR93","first-page":"13","volume":"33","author":"H Koyuncuoglu","year":"1995","unstructured":"Koyuncuoglu H (1995) The combination of tizanidine markedly improves the treatment with dextromethorphan of heroin addicted outpatients. Int J Clin Pharmacol Ther 33(1):13\u20139","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"430_CR94","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1213\/00000539-200301000-00041","volume":"96","author":"MF Davies","year":"2003","unstructured":"Davies MF et al (2003) Dexmedetomidine fails to cause hyperalgesia after cessation of chronic administration. Anesth Analg 96(1):195\u2013200, table of contents","journal-title":"Anesth Analg"},{"issue":"3","key":"430_CR95","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1213\/00000539-199609000-00030","volume":"83","author":"Y Hayashi","year":"1996","unstructured":"Hayashi Y, Guo TZ, Maze M (1996) Hypnotic and analgesic effects of the alpha2-adrenergic agonist dexmedetomidine in morphine-tolerant rats. Anesth Analg 83(3):606\u201310","journal-title":"Anesth Analg"},{"issue":"13","key":"430_CR96","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.2146\/ajhp100257","volume":"68","author":"A Oschman","year":"2011","unstructured":"Oschman A, McCabe T, Kuhn RJ (2011) Dexmedetomidine for opioid and benzodiazepine withdrawal in pediatric patients. Am J Health Syst Pharm 68(13):1233\u20138","journal-title":"Am J Health Syst Pharm"},{"issue":"4","key":"430_CR97","doi-asserted-by":"crossref","first-page":"187","DOI":"10.5055\/jom.2008.0024","volume":"4","author":"JD Tobias","year":"2008","unstructured":"Tobias JD (2008) Subcutaneous dexmedetomidine infusions to treat or prevent drug withdrawal in infants and children. J Opioid Manag 4(4):187\u201391","journal-title":"J Opioid Manag"},{"issue":"4","key":"430_CR98","doi-asserted-by":"crossref","first-page":"201","DOI":"10.5055\/jom.2006.0031","volume":"2","author":"JD Tobias","year":"2006","unstructured":"Tobias JD (2006) Dexmedetomidine to treat opioid withdrawal in infants following prolonged sedation in the pediatric ICU. J Opioid Manag 2(4):201\u20135","journal-title":"J Opioid Manag"},{"issue":"9","key":"430_CR99","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1097\/01.CCM.0000178183.21883.23","volume":"33","author":"JC Finkel","year":"2005","unstructured":"Finkel JC, Johnson YJ, Quezado ZM (2005) The use of dexmedetomidine to facilitate acute discontinuation of opioids after cardiac transplantation in children. Crit Care Med 33(9):2110\u20132","journal-title":"Crit Care Med"},{"issue":"9","key":"430_CR100","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/01.SMJ.0000053557.75799.09","volume":"96","author":"JD Tobias","year":"2003","unstructured":"Tobias JD, Berkenbosch JW, Russo P (2003) Additional experience with dexmedetomidine in pediatric patients. South Med J 96(9):871\u20135","journal-title":"South Med J"},{"issue":"7","key":"430_CR101","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.recesp.2013.01.015","volume":"66","author":"L Vega","year":"2013","unstructured":"Vega L et al (2013) Prevention of opioid withdrawal syndrome after pediatric heart transplantation: usefulness of dexmedetomidine. Rev Esp Cardiol (Engl Ed) 66(7):593\u20135","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"3","key":"430_CR102","doi-asserted-by":"crossref","first-page":"251","DOI":"10.4103\/0973-1075.92353","volume":"17","author":"SP Upadhyay","year":"2011","unstructured":"Upadhyay SP et al (2011) Dexmedetomidine infusion to facilitate opioid detoxification and withdrawal in a patient with chronic opioid abuse. Indian J Palliat Care 17(3):251\u20134","journal-title":"Indian J Palliat Care"},{"issue":"4","key":"430_CR103","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1213\/01.ANE.0000050773.70232.08","volume":"96","author":"AS Multz","year":"2003","unstructured":"Multz AS (2003) Prolonged dexmedetomidine infusion as an adjunct in treating sedation-induced withdrawal. Anesth Analg 96(4):1054\u20135, table of contents","journal-title":"Anesth Analg"},{"issue":"5","key":"430_CR104","doi-asserted-by":"crossref","first-page":"337","DOI":"10.5055\/jom.2011.0074","volume":"7","author":"DA Nasr","year":"2011","unstructured":"Nasr DA et al (2011) Ultra-rapid opiate detoxification using dexmedetomidine under general anesthesia. J Opioid Manag 7(5):337\u201344","journal-title":"J Opioid Manag"},{"issue":"12","key":"430_CR105","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1111\/j.1526-4637.2010.00973.x","volume":"11","author":"M Belgrade","year":"2010","unstructured":"Belgrade M, Hall S (2010) Dexmedetomidine infusion for the management of opioid-induced hyperalgesia. Pain Med 11(12):1819\u201326","journal-title":"Pain Med"},{"key":"430_CR106","first-page":"Cd002024","volume":"3","author":"L Gowing","year":"2014","unstructured":"Gowing L et al (2014) Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev 3:Cd002024","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"430_CR107","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1360-0443.2002.00037.x","volume":"97","author":"LR Gowing","year":"2002","unstructured":"Gowing LR et al (2002) Alpha2-adrenergic agonists in opioid withdrawal. Addiction 97(1):49\u201358","journal-title":"Addiction"},{"issue":"9","key":"430_CR108","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1345\/aph.1M161","volume":"43","author":"BL Honey","year":"2009","unstructured":"Honey BL et al (2009) Alpha2-receptor agonists for treatment and prevention of iatrogenic opioid abstinence syndrome in critically ill patients. Ann Pharmacother 43(9):1506\u201311","journal-title":"Ann Pharmacother"},{"issue":"24","key":"430_CR109","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMra0809890","volume":"362","author":"NL Benowitz","year":"2010","unstructured":"Benowitz NL (2010) Nicotine addiction. N Engl J Med 362(24):2295\u2013303","journal-title":"N Engl J Med"},{"issue":"1507","key":"430_CR110","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1098\/rstb.2008.0095","volume":"363","author":"A Markou","year":"2008","unstructured":"Markou A (2008) Review. Neurobiology of nicotine dependence. Philos Trans R Soc Lond B Biol Sci 363(1507):3159\u201368","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"1","key":"430_CR111","first-page":"4","volume":"6","author":"MS D'Souza","year":"2011","unstructured":"D'Souza MS, Markou A (2011) Neuronal mechanisms underlying development of nicotine dependence: implications for novel smoking-cessation treatments. Addict Sci Clin Pract 6(1):4\u201316","journal-title":"Addict Sci Clin Pract"},{"key":"430_CR112","doi-asserted-by":"crossref","unstructured":"D\u2019Souza MS Markou A. The \u201cstop\u201d and \u201cgo\u201d of nicotine dependence: role of GABA and glutamate. Cold Spring Harb Perspect Med. 2013. 3 (6).","DOI":"10.1101\/cshperspect.a012146"},{"issue":"2\u20133","key":"430_CR113","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.neuropharm.2010.09.013","volume":"60","author":"H Yamada","year":"2011","unstructured":"Yamada H, Bruijnzeel AW (2011) Stimulation of alpha2-adrenergic receptors in the central nucleus of the amygdala attenuates stress-induced reinstatement of nicotine seeking in rats. Neuropharmacology 60(2\u20133):303\u201311","journal-title":"Neuropharmacology"},{"issue":"2","key":"430_CR114","doi-asserted-by":"crossref","first-page":"R58","DOI":"10.1186\/cc8954","volume":"14","author":"O Lucidarme","year":"2010","unstructured":"Lucidarme O et al (2010) Nicotine withdrawal and agitation in ventilated critically ill patients. Crit Care 14(2):R58","journal-title":"Crit Care"},{"issue":"3","key":"430_CR115","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14622200701188919","volume":"9","author":"JR Hughes","year":"2007","unstructured":"Hughes JR (2007) Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res 9(3):315\u201327","journal-title":"Nicotine Tob Res"},{"issue":"4676","key":"430_CR116","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1126\/science.6387913","volume":"226","author":"AH Glassman","year":"1984","unstructured":"Glassman AH et al (1984) Cigarette craving, smoking withdrawal, and clonidine. Science 226(4676):864\u20136","journal-title":"Science"},{"issue":"1","key":"430_CR117","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/clpt.1994.11","volume":"55","author":"S Gourlay","year":"1994","unstructured":"Gourlay S et al (1994) A placebo-controlled study of three clonidine doses for smoking cessation. Clin Pharmacol Ther 55(1):64\u20139","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"430_CR118","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/clpt.1993.205","volume":"54","author":"AH Glassman","year":"1993","unstructured":"Glassman AH et al (1993) Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers. Clin Pharmacol Ther 54(6):670\u20139","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"430_CR119","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/j.1360-0443.1988.tb03029.x","volume":"83","author":"W Hao","year":"1988","unstructured":"Hao W, Young D (1988) Effect of clonidine on cigarette cessation and in the alleviation of withdrawal symptoms. Br J Addict 83(10):1221\u20136","journal-title":"Br J Addict"},{"issue":"21","key":"430_CR120","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1001\/jama.1989.03430210053029","volume":"262","author":"P Franks","year":"1989","unstructured":"Franks P, Harp J, Bell B (1989) Randomized, controlled trial of clonidine for smoking cessation in a primary care setting. Jama 262(21):3011\u20133","journal-title":"Jama"},{"issue":"9","key":"430_CR121","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1001\/archinte.1988.00380090095023","volume":"148","author":"SA Ornish","year":"1988","unstructured":"Ornish SA, Zisook S, McAdams LA (1988) Effects of transdermal clonidine treatment on withdrawal symptoms associated with smoking cessation. A randomized, controlled trial. Arch Intern Med 148(9):2027\u201331","journal-title":"Arch Intern Med"},{"issue":"10","key":"430_CR122","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1001\/archinte.1992.00400220083015","volume":"152","author":"AV Prochazka","year":"1992","unstructured":"Prochazka AV et al (1992) Transdermal clonidine reduced some withdrawal symptoms but did not increase smoking cessation. Arch Intern Med 152(10):2065\u20139","journal-title":"Arch Intern Med"},{"issue":"5","key":"430_CR123","first-page":"435","volume":"62","author":"JL Cervantes Escarcega","year":"1992","unstructured":"Cervantes Escarcega JL, Guadalajara Boo JF (1992) Effect of transdermal therapy with clonidine on suppression symptoms secondary to smoking cessation. Arch Inst Cardiol Mex 62(5):435\u201340","journal-title":"Arch Inst Cardiol Mex"},{"issue":"1","key":"430_CR124","first-page":"2085","volume":"96","author":"DE Hilleman","year":"1989","unstructured":"Hilleman DE et al (1989) Double-blind, placebo-controlled, evaluation of transdermal clonidine in smoking cessation. Chest 96(1):2085","journal-title":"Chest"},{"issue":"3","key":"430_CR125","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1037\/1064-1297.4.3.285","volume":"4","author":"RBR Niaura","year":"1996","unstructured":"Niaura RBR, Goldstein MG, Murphy JK, Abrams DB (1996) Transdermal clonidine for smoking cessation: a double-blind randomized dose\u2013response study. Exp Clin Psychopharmacol 4(3):285\u2013291","journal-title":"Exp Clin Psychopharmacol"},{"issue":"9","key":"430_CR126","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1177\/106002809302700901","volume":"27","author":"DE Hilleman","year":"1993","unstructured":"Hilleman DE et al (1993) Randomized, controlled trial of transdermal clonidine for smoking cessation. Ann Pharmacother 27(9):1025\u20138","journal-title":"Ann Pharmacother"},{"issue":"3","key":"430_CR127","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/02791072.1989.10472177","volume":"21","author":"KL Sees","year":"1989","unstructured":"Sees KL, Stalcup SA (1989) Combining clonidine and nicotine replacement for treatment of nicotine withdrawal. J Psychoactive Drugs 21(3):355\u20139","journal-title":"J Psychoactive Drugs"},{"key":"430_CR128","first-page":"Cd009329","volume":"5","author":"K Cahill","year":"2013","unstructured":"Cahill K et al (2013) Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 5:Cd009329","journal-title":"Cochrane Database Syst Rev"},{"key":"430_CR129","doi-asserted-by":"crossref","unstructured":"Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst Rev, 2004 (3): p. Cd000058.","DOI":"10.1002\/14651858.CD000058.pub2"},{"issue":"5","key":"430_CR130","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/0002-8703(73)90165-8","volume":"85","author":"L Hansson","year":"1973","unstructured":"Hansson L et al (1973) Blood pressure crisis following withdrawal of clonidine (Catapres, Catapresan), with special reference to arterial and urinary catecholamine levels, and suggestions for acute management. Am Heart J 85(5):605\u201310","journal-title":"Am Heart J"},{"key":"430_CR131","doi-asserted-by":"crossref","unstructured":"Whalen LD, et al. Long-term dexmedetomidine use and safety profile among critically ill children and neonates. Pediatr Crit Care Med, 2014.","DOI":"10.1097\/PCC.0000000000000200"},{"issue":"1","key":"430_CR132","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/0960327112454896","volume":"32","author":"A Kukoyi","year":"2013","unstructured":"Kukoyi A et al (2013) Two cases of acute dexmedetomidine withdrawal syndrome following prolonged infusion in the intensive care unit: report of cases and review of the literature. Hum Exp Toxicol 32(1):107\u201310","journal-title":"Hum Exp Toxicol"},{"key":"430_CR133","unstructured":"FDA Med Watch. [cited 2014 8\/30]; Available from: http:\/\/www.fda.gov\/Safety\/Medwatch\/Safety Information\/ucm233675.htm."},{"issue":"1","key":"430_CR134","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1300\/J251v07n01_02","volume":"7","author":"P Cushman Jr","year":"1987","unstructured":"Cushman P Jr (1987) Clonidine and alcohol withdrawal. Adv Alcohol Subst Abuse 7(1):17\u201328","journal-title":"Adv Alcohol Subst Abuse"},{"issue":"4","key":"430_CR135","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jama.1980.03300300021018","volume":"243","author":"MS Gold","year":"1980","unstructured":"Gold MS et al (1980) Opiate withdrawal using clonidine. A safe, effective, and rapid nonopiate treatment. Jama 243(4):343\u20136","journal-title":"Jama"},{"issue":"11","key":"430_CR136","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1001\/archpsyc.1981.01780360089010","volume":"38","author":"DS Charney","year":"1981","unstructured":"Charney DS et al (1981) The clinical use of clonidine in abrupt withdrawal from methadone. Effects on blood pressure and specific signs and symptoms. Arch Gen Psychiatry 38(11):1273\u20137","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"430_CR137","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/archpsyc.1985.01790340041006","volume":"42","author":"DR Jasinski","year":"1985","unstructured":"Jasinski DR, Johnson RE, Kocher TR (1985) Clonidine in morphine withdrawal. Differential effects on signs and symptoms. Arch Gen Psychiatry 42(11):1063\u20136","journal-title":"Arch Gen Psychiatry"},{"issue":"1\u20132","key":"430_CR138","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0376-8716(96)01289-6","volume":"43","author":"J Bearn","year":"1996","unstructured":"Bearn J, Gossop M, Strang J (1996) Randomised double-blind comparison of lofexidine and methadone in the in-patient treatment of opiate withdrawal. Drug Alcohol Depend 43(1\u20132):87\u201391","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"430_CR139","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0376-8716(96)01316-6","volume":"44","author":"A Kahn","year":"1997","unstructured":"Kahn A et al (1997) Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital. Drug Alcohol Depend 44(1):57\u201361","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"430_CR140","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0376-8716(98)00030-1","volume":"50","author":"J Bearn","year":"1998","unstructured":"Bearn J, Gossop M, Strang J (1998) Accelerated lofexidine treatment regimen compared with conventional lofexidine and methadone treatment for in-patient opiate detoxification. Drug Alcohol Depend 50(3):227\u201332","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"430_CR141","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/13556210020040226","volume":"6","author":"J Bearn","year":"2001","unstructured":"Bearn J et al (2001) The impact of naloxone\/lofexidine combination treatment on the opiate withdrawal syndrome. Addict Biol 6(2):147\u2013156","journal-title":"Addict Biol"},{"issue":"4","key":"430_CR142","first-page":"295","volume":"12","author":"T Beswick","year":"2003","unstructured":"Beswick T et al (2003) The effectiveness of combined naloxone\/lofexidine in opiate detoxification: results from a double-blind randomized and placebo-controlled trial. Am J Addict 12(4):295\u2013305","journal-title":"Am J Addict"}],"container-title":["Journal of Medical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-014-0430-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13181-014-0430-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-014-0430-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-014-0430-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T04:24:07Z","timestamp":1744172647000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13181-014-0430-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,20]]},"references-count":142,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["430"],"URL":"https:\/\/doi.org\/10.1007\/s13181-014-0430-3","relation":{},"ISSN":["1556-9039","1937-6995"],"issn-type":[{"value":"1556-9039","type":"print"},{"value":"1937-6995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,20]]},"assertion":[{"value":"20 September 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}